Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review ; volume:10 ; number:1 ; day:9 ; month:2 ; year:2024 ; pages:1-13 ; date:12.2024
Future Journal of Pharmaceutical Sciences ; 10, Heft 1 (9.2.2024), 1-13, 12.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Bera, Dayeeta
Roy, Dattatreya
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43094-024-00590-9
- URN
-
urn:nbn:de:101:1-2404180702240.419349104248
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bera, Dayeeta
- Roy, Dattatreya
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma
Aberrant synaptophysin expression in classic Hodgkin lymphoma
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Bob-1 is expressed in classic Hodgkin lymphoma
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Cutaneous Hodgkin’s lymphoma
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma
Aberrant synaptophysin expression in classic Hodgkin lymphoma
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Bob-1 is expressed in classic Hodgkin lymphoma
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Cutaneous Hodgkin’s lymphoma
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma
Aberrant synaptophysin expression in classic Hodgkin lymphoma
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Bob-1 is expressed in classic Hodgkin lymphoma
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Cutaneous Hodgkin’s lymphoma